Baidu
map
J ANAL TOXICOL 润色咨询

JOURNAL OF ANALYTICAL TOXICOLOGY

出版年份:1977 年文章数:1814 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:16.9% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2021-12-29 衣谷

    RUNINGTITLE是必须的么?

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2021-12-29 ms6000000264964247

    RUNNINGTITLE和TITLE的区别?

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2019-04-18 二氯卡宾

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2019-04-08 二氯卡宾

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。
    小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。
    时间列表:
    2018.11.03——submit;
    2019.01.12—— major revision;
    2019.02.21——revision submit;
    2019.04.08——accept。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2017-07-18 yang_liping1

    虽然今年没有什么大变化,以后再看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2013-09-09 匿名用户

    审稿速度:2.0 | 投稿命中率:75.0
    经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1092431, encodeId=3f971092431dc, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092432, encodeId=eda61092432e7, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569697, encodeId=f7c156969e9d, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:小硕一枚,毒物分析方向,第一篇SCI,历经重重困难,终于被接收啦! 一审:2个月多。要求大修。审稿人仔细认真,意见比较中肯,对后续修改帮助很大,没要补实验。 大修返回后,1.5个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569250, encodeId=b317569250f4, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一篇SCI,投稿JAT,过程很煎熬,不过accept之后超级开心。 <br> 小硕一枚,做体内毒物分析。一审周期:2个月多一点,最后给了大修,没要求补实验。审稿人很认真,提出的问题很专业,对我后期修改帮助很大,真心感谢。大修后,1个半月接收。 <br> 时间列表: <br> 2018.11.03——submit; <br> 2019.01.12—— major revision; <br> 2019.02.21——revision submit; <br> 2019.04.08——accept。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/24/5df21ac135d837ba23b9681341de6726.jpg, createdBy=99602056210, createdName=二氯卡宾, createdTime=Mon Apr 08 14:39:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=540121, encodeId=9661540121b3, content=虽然今年没有什么大变化,以后再看看, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_liping1, createdTime=Tue Jul 18 18:38:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498881, encodeId=a25c49888189, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享:这个杂志挺厚道,审稿速度快,有一定新意跟毒理,毒性代谢产物相关容易中,偏重于临床相关, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Sep 09 16:30:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819098, encodeId=f24b819098e4, content=这个杂志如何啊? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6f95414014, createdName=ms9686134410729756, createdTime=Thu Apr 19 00:43:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2012-04-19 ms9686134410729756

    这个杂志如何啊?

    0

共10条页码: 1/1页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map